1FreifeldAG, BowEJ, SepkowitzKA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2011, 52(4):427-431. doi: 10.1093/cid/ciq147.
2AverbuchD, OraschC, CordonnierC, et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia [J]. Haematologica, 2013, 98(12):1826-1835. doi: 10.3324/haematol.2013.091025.
3AverbuchD, CordonnierC, LivermoreDM, et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: guidelines of the 4th European Conference on Infections in Leukemia (ECIL-4, 2011)[J]. Haematologica, 2013, 98(12):1836-1847. doi: 10.3324/haematol.2013.091330.
6Clinical and Laboratory Standards Institute (CLSI)/NCCLS.Performance Standards for Antimicrobial Susceptibility testing Standards:Fifteenth Informational Supplement[S].2005,M100-S15.
7WHO Global strategy for containment of antimicrobial resistance.WHO/CDS/CSR/DRS/2001.2.
8The Copenhagen Recommendations-Report from the invitrtional EU conference on the microbial threat.www microbial threat.dk edited by Vibeke Thamdrup Rosdahl.
9Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge[J]. N Engl J Med, 2009, 360(5) : 439-443.
10Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing[S]. Tweenty-first in- formational supplement, 2011, M100-S21 Vol 31 No. 1.
